Recently it has been shown that the combination of a high-risk breast cancer PRS and CHEK2_1100delC equated to a breast cancer lifetime risk equivalent to that of a PALB2 PGV alone.33 These data suggest that CHEK2_1100delC should be incorporated into diagnostic breast cancer genetic testing panels as this knowledge of moderate risk PGVs, combined with a PRS, will become part of routine practice in breast cancer risk assessment. Here, PALB2 is linked to breast carcinoma.